APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma
← catalyst calendarSponsored by Ascentage Pharma Group Inc. (industry) · AAPG — their whole pipeline →.
Phase
Phase 1/2
Status
Unknown status
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
51estimated
Sites
4
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-06-14 | actual | When the study began enrolling |
| Primary completion | Sep 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2022-01-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-01-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- NHL, Adult
Interventions
- Drug: APG-1252 — also filed as Pelcitoclax
- Drug: Chidamide
Primary outcomes
what the primary-completion date above is the date OFDose Limiting Toxicity (DLT)
measured 28 days
Maximally tolerated dose (MTD)
measured 28 days
Permalink · AAPG's whole pipeline · Catalyst calendar · Every registered study · What changed